Saadati Saeede, Mason Taitum, Godini Rasoul, Vanky Eszter, Teede Helena, Mousa Aya
Monash Centre for Health Research and Implementation (MCHRI), Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia.
Development and Stem Cells Program, Monash Biomedicine Discovery Institute and Department of Anatomy and Developmental Biology, Monash University, Melbourne, Victoria, Australia.
Diabetes Obes Metab. 2025 Jun;27 Suppl 3(Suppl 3):31-47. doi: 10.1111/dom.16422. Epub 2025 May 6.
Metformin, a synthetic biguanide, is widely used to manage type 2 diabetes, and is commonly prescribed in polycystic ovary syndrome (PCOS) to address insulin resistance and associated metabolic and reproductive disturbances. PCOS is characterised by hormonal imbalances such as hyperandrogenism and anovulation, metabolic abnormalities including insulin resistance and increased cardiometabolic risk, and higher rates of pregnancy complications. However, the role of metformin in the multifaceted nature of PCOS remains debated. This review synthesises the mechanisms of action of metformin and its effects on metabolic, hormonal, reproductive, and pregnancy-related outcomes in PCOS. In non-pregnant women, metformin improves insulin resistance, menstrual regularity, and androgen levels, particularly in those with obesity or insulin resistance, and may enhance fertility when combined with other treatments. However, it is not effective as a first-line therapy for weight loss, ovulation induction, or treatment of clinical hyperandrogenic features, including hirsutism or acne. In pregnancy, metformin may reduce early pregnancy loss, miscarriage, and preterm birth, though findings for gestational diabetes and preeclampsia are inconsistent. Evidence is limited by study heterogeneity, varying diagnostic criteria, and the use of aggregate data in meta-analyses, all of which make interpretation challenging. Future research should prioritise well-powered clinical trials, individual patient data meta-analyses, and longer-term follow-up studies, particularly in pregnancy, to better define the populations most likely to benefit from metformin use across the PCOS spectrum. PLAIN LANGUAGE SUMMARY: Polycystic ovary syndrome (PCOS) is a common condition that affects up to 1 in 10 women of reproductive age. It is characterised by irregular or absent periods, signs of elevated male hormones (high androgens or excess hair growth), and/or polycystic ovaries seen on ultrasound. These features can lead to fertility problems, acne, psychological distress, and an increased risk of various disorders such as depression, type 2 diabetes and heart disease. Many women with PCOS also experience challenges during pregnancy, including a higher risk of miscarriage, preterm birth, and gestational diabetes. Metformin is a medication most often used to manage diabetes. In women with PCOS, it can help improve how the body responds to insulin, which may also reduce male hormone levels, improve menstrual cycles, and support fertility. This review examines the role of metformin in treating PCOS-both before and during pregnancy-by summarising key findings from the available evidence. In women who are not pregnant, metformin can help improve insulin resistance, hormone levels, and menstrual regularity, particularly among those who are overweight or have signs of insulin resistance. However, metformin alone is not a first-choice treatment for weight loss, ovulation problems, or symptoms such as acne and unwanted hair growth. When combined with other treatments, such as hormone therapy or fertility medications, it may offer additional benefits. During pregnancy, metformin is considered safe for use in women with PCOS and may lower the risk of early pregnancy loss and preterm birth. However, its effects on preventing gestational diabetes or high blood pressure are less clear, with mixed results across studies. Some research suggests that babies exposed to metformin in the womb may have slightly larger head sizes or a higher risk of being overweight in early childhood, but the long-term health effects remain unknown. Overall, metformin can be a helpful part of treatment for some women with PCOS, especially those with insulin resistance or certain pregnancy risks. Still, it is not a one-size-fits-all solution. More high-quality research is needed to better understand which women benefit most and to assess any long-term effects on children exposed to metformin during pregnancy.
二甲双胍是一种合成双胍类药物,广泛用于治疗2型糖尿病,在多囊卵巢综合征(PCOS)中也常被用于解决胰岛素抵抗以及相关的代谢和生殖紊乱问题。PCOS的特征包括激素失衡,如高雄激素血症和无排卵;代谢异常,包括胰岛素抵抗和心血管代谢风险增加;以及较高的妊娠并发症发生率。然而,二甲双胍在PCOS多方面特性中的作用仍存在争议。本综述综合了二甲双胍的作用机制及其对PCOS患者代谢、激素、生殖和妊娠相关结局的影响。在非妊娠女性中,二甲双胍可改善胰岛素抵抗、月经规律和雄激素水平,尤其是在肥胖或有胰岛素抵抗的女性中,与其他治疗联合使用时可能会提高生育能力。然而,它作为减肥、诱导排卵或治疗临床高雄激素特征(包括多毛症或痤疮)的一线治疗方法并不有效。在孕期,二甲双胍可能会降低早期妊娠丢失、流产和早产的风险,尽管关于妊娠期糖尿病和先兆子痫的研究结果并不一致。研究的异质性、不同的诊断标准以及荟萃分析中汇总数据的使用,都限制了证据,所有这些都使得解读具有挑战性。未来的研究应优先开展样本量充足的临床试验、个体患者数据荟萃分析以及长期随访研究,尤其是在孕期,以便更好地确定在整个PCOS范围内最可能从使用二甲双胍中获益的人群。
多囊卵巢综合征(PCOS)是一种常见疾病,影响着高达十分之一的育龄女性。其特征为月经不规律或闭经、男性激素升高的迹象(高雄激素或毛发过度生长)和/或超声检查可见的多囊卵巢。这些特征可导致生育问题、痤疮、心理困扰以及患抑郁症、2型糖尿病和心脏病等各种疾病的风险增加。许多患有PCOS的女性在孕期也会面临挑战,包括流产、早产和妊娠期糖尿病的风险更高。二甲双胍是最常用于治疗糖尿病的药物。在患有PCOS的女性中,它有助于改善身体对胰岛素的反应,这也可能降低男性激素水平、改善月经周期并支持生育能力。本综述通过总结现有证据的主要发现,探讨了二甲双胍在治疗PCOS(孕前和孕期)中的作用。在未怀孕的女性中,二甲双胍有助于改善胰岛素抵抗、激素水平和月经规律,特别是在超重或有胰岛素抵抗迹象的女性中。然而,单独使用二甲双胍并非减肥、排卵问题或痤疮和多毛等症状的首选治疗方法。与其他治疗方法(如激素疗法或生育药物)联合使用时,它可能会带来额外的益处。在孕期,二甲双胍被认为对患有PCOS的女性使用是安全的,可能会降低早期妊娠丢失和早产的风险。然而,其对预防妊娠期糖尿病或高血压的作用尚不清楚,各项研究结果不一。一些研究表明,在子宫内接触二甲双胍的婴儿可能头部尺寸略大或幼儿期超重风险更高,但长期健康影响仍未知。总体而言,二甲双胍对一些患有PCOS的女性可能是治疗的有益组成部分,尤其是那些有胰岛素抵抗或某些妊娠风险的女性。不过,它并非适用于所有情况的解决方案。需要更多高质量的研究来更好地了解哪些女性获益最大,并评估孕期接触二甲双胍对儿童的任何长期影响。